BC281 treatment in combination with ALT-803 extended survival and decreased leukemia burden as compared to BC462 control plus ALT-803 or AL-T803 alone (Fig. 6I, Supplementary Fig. 26A). The gene discussed is GPT; the disease is leukemia.